Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.02 USD
Change Today -0.0043 / -17.55%
Volume 20.0K
OMBP On Other Exchanges
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

omni bio pharmaceutical inc (OMBP) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/19/14 - $0.45
52 Week Low
06/15/15 - $0.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

omni bio pharmaceutical inc (OMBP) Related Businessweek News

No Related Businessweek News Found

omni bio pharmaceutical inc (OMBP) Details

Omni Bio Pharmaceutical, Inc. operates as a biopharmaceutical company in the United States. It holds a license to use patent for the treatment of diabetes using plasma-derived alpha-1 antitrypsin (p-AAT), a protein that is purified from human blood. The company also holds licenses for the use of patents and patent applications covering the use of p-AAT in the treatment of cellular transplantation and graft rejection, radiation protection, bacterial and viral diseases, myocardial remodeling, and inflammatory bowel disease indications. In addition, it holds licenses for patent applications covering compositions of various Fc-AAT constructs. Omni Bio Pharmaceutical, Inc. was founded in 2006 and is headquartered in Fort Collins, Colorado.

1 Employees
Last Reported Date: 06/16/14
Founded in 2006

omni bio pharmaceutical inc (OMBP) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $180.0K
Chief Scientific Officer and Member of Scient...
Total Annual Compensation: $90.0K
Compensation as of Fiscal Year 2014.

omni bio pharmaceutical inc (OMBP) Key Developments

Omni Bio Pharmaceutical, Inc. expected to report Q1 2016 results on August 31, 2015. This event was calculated by Capital IQ (Created on August 25, 2015).

Omni Bio Pharmaceutical, Inc. expected to report Q1 2016 results on August 31, 2015. This event was calculated by Capital IQ (Created on August 25, 2015).

Omni Bio Pharmaceutical, Inc. Announces Clinical Data for Use of Alpha-1 Antitrypsin in Steroid-Resistant Graft Versus Host Disease

Omni Bio Pharmaceutical, Inc. announced the presentation of interim clinical data demonstrating the ability of plasma-derived alpha-1 antitrypsin (AAT) to reduce inflammation and promote healing of damaged tissues in patients with graft-versus-host disease (GvHD), a common and potentially life-threatening complication following bone marrow transplantation. The positive interim results support continued clinical studies of this novel approach to treating GvHD and also highlight the potential value of Omni Bio's novel, recombinant AAT candidate, AAT-Fc, currently in preclinical development. Data from the first seven patients to complete the Phase 1/2 study were presented at the 56th annual meeting of the American Society of Hematology in San Francisco by Omni Bio's academic collaborators from the University of Washington and the Fred Hutchinson Cancer Research Center. Following allogeneic stem cell transplants to treat leukemic malignancies, the patients in the study all developed severe acute GvHD symptoms (severe diarrhea, loss of mucosal lining in the gut) but did not respond satisfactorily to standard of treatment including high dose steroids. The patients then received intravenous doses of plasma-derived AAT every other day for a total of 8 doses (15 days) in an attempt to alleviate their GvHD symptoms. The investigators concluded that the administration of AAT as a safe salvage therapy for gut GvHD is feasible without clinically relevant toxicity. Stool sampling showed a decrease in intestinal AAT clearance and endoscopic evaluation confirmed healing of the bowel mucosa. The overall findings suggest that further evaluation of AAT as treatment for steroid refractory GvHD, or as first line therapy, is warranted.

Omni Bio Pharmaceutical, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 03:30 PM

Omni Bio Pharmaceutical, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 03:30 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Bruce E. Schneider, Chairman and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMBP:US $0.02 USD -0.0043

OMBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OMBP.
View Industry Companies

Industry Analysis


Industry Average

Valuation OMBP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OMNI BIO PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at